Pulmonx Corp. (LUNG)

Pulmonx Corp. has experienced several significant stock events in the past six months. Leadership changes occurred in October 2025 with the reappointment of Glen French as President and CEO, and the appointment of Derrick Sung as COO and CFO. Preliminary Q3 2025 revenue surpassed estimates at approximately $21.5 million. Q2 2025 revenue beat analyst estimates, but the company reported a loss of ($0.38) earnings per share (EPS). The company revised its full-year 2025 revenue guidance to $90-92 million. The company's share price has declined significantly. Pulmonx participated in investor conferences in August and September 2025.

Demand for Pulmonx Corp.'s products and services can be subject to seasonality due to the elective nature of the procedures, which may lead to a slowing of demand at the beginning and end of the year, as well as during summer months. Global pandemics or outbreaks of infectious diseases, such as COVID-19, can affect the number of patients treated with Zephyr Valves.

Pulmonx Corp. is a medical technology company focused on minimally invasive treatments for severe emphysema (COPD). Their product portfolio includes the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, StratX® Lung Analysis Platform, and LungTraX Platform. The Zephyr Valve is commercially available in over 25 countries and is recognized in global treatment guidelines.

Pulmonx generates revenue through sales to distributors and hospitals across the United States, Europe, the Middle East, Africa, and Asia Pacific. The Zephyr Valve is commercially available in more than 25 countries, with ongoing post-approval studies in Japan and growth potential in China. The company has offices in Redwood City, California, and Neuchâtel, Switzerland.

Pulmonx is recognized as a global leader in minimally invasive treatments for COPD, with its Zephyr Valve receiving FDA "breakthrough device" designation and being considered a standard of care in over 25 countries. Leadership transitions, slower U.S. market adoption, partnerships, and educational initiatives have affected Pulmonx Corp.'s reputation in the past year. Pulmonx partnered with the American Lung Association to launch new educational initiatives for COPD patients and providers in November 2024. Pulmonx and Jaeger™ announced a strategic partnership to integrate data qualification capabilities into SentrySuite™ in August 2025.

Pulmonx Corporation has a mixed ownership structure, including institutional investors, insiders, and public/individual investors. As of October 17, 2025, there are 260 institutional owners and shareholders holding a total of 43,097,708 shares. Approximately 6.86% of the company's stock is owned by insiders. Insider trading activity in the last 24 months shows more selling than buying.